GSK’s Rotarix Gets FDA Vaccines Advisory Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Feb. 20 meeting to focus on product safety for Rotarix, which would have a shorter dosing schedule than Merck’s RotaTeq and target more virus types.